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 SYNOPSIS (250 words) 41 
OBJECTIVES: To describe the pattern of drug resistance at virologic failure (VF) in the 42 
NEAT001/ANRS143 trial (first-line treatment with ritonavir-boosted darunavir plus either 43 
tenofovir/emtricitabine or raltegravir). 44 
METHODS: A genotypic testing was performed at baseline for reverse transcriptase (RT) and 45 
protease genes and for RT, protease and integrase (IN) genes for patients with a confirmed 46 
viral load (VL) > 50 copies/mL or any single VL > 500 copies/mL at or after week 32. 47 
RESULTS: A resistance test was obtained for 110/805 (13.7%) randomised participants 48 
qualifying for resistance analysis (61/401 of RAL arm and 49/404 of TDF/FTC arm). No 49 
resistance associated mutation (RAM) was observed in the TDF/FTC+DRV/r arm, and all 50 
further analyses are limited to the RAL+DRV/r arm. In this group, 15/55 (27.3%) participants 51 
had viruses with IN RAM (12 N155H alone, 1 N155H + Q148R, 1 F121Y and 1 Y143C), 2/53 52 
(3.8%) with NtRTI RAM (K65R, M41L), and 1/57 (1.8%) with primary protease RAM (L76V). 53 
The frequency of IN mutations at failure was significantly associated with baseline VL: 7.1% 54 
for VL <100,000 copies/mL, 25.0% for VL ≥100-500,000 copies/mL, and 53.8% for VL 55 
≥500,000 copies/mL (PTREND=0.007). Of note, 4/15 participants with IN RAM had a VL <200 56 
copies/mL at time of testing.  57 
CONCLUSION: In the NEAT001/ANRS143 trial, there were no RAM at VF in the standard 58 
DRV/r+TDF/FTC regimen, contrasting with rate of 29.5% in the DRV/r+RAL NtRTI-sparing 59 
regimen (mostly IN mutations). Cumulative risk of IN RAM after 96 weeks follow-up in 60 
participants initiating antiretroviral therapy with DRV/r + RAL was 3.9%.  61 
 62 
 63 
 INTRODUCTION 64 
In Europe, a combination of 2 nucleoside or nucleotide analogue reverse transcriptase 65 
inhibitors (NtRTI) and a non-nucleoside analogue reverse transcriptase inhibitor (NNRTI), a 66 
ritonavir boosted protease inhibitor (PI) or an integrase strand transfer inhibitor (ISTI) is 67 
recommended for initial therapy for HIV-1 infected patients. 1 The tolerability and toxicity 68 
profile of NtRTIs in particular the cardiovascular risk with abacavir and bone and renal 69 
toxicity with tenofovir has led to the research of NtRTI-sparing alternative antiretroviral 70 
combinations. 2–6 NEAT 001/ANRS 143 was an European open-label, non-inferiority, phase III 71 
randomised trial that evaluated the efficacy of the NtRTI-sparing regimen raltegravir plus 72 
darunavir and ritonavir (RAL+DRV/r) versus a standard of care regimen 73 
tenofovir/emtricitabine plus darunavir and ritonavir (TDF/FTC+DRV/r) in treatment-naïve 74 
adults. This study showed the non-inferiority of the NtRTI sparing strategy (RAL+DRV/r arm) 75 
versus the standard arm but only in participants with baseline CD4 cell counts > 200 76 
cells/mm3. 7 As described in the main study report, genotypic analysis was done at screening 77 
and at all visits from 32 weeks onwards for participants who had HIV-1 RNA ≥ 500 copies/mL. 78 
Among participants who underwent genotype testing to assess emerging resistance at the 79 
time of virological failure, treatment-emergent resistance was seen in no participants in the 80 
standard of care-group and in six (21%) of 29 in the NtRTI sparing group, five of whom had 81 
resistance to integrase (IN) and one to NtRTI. 7 While IN-associated resistance frequency and 82 
profile are somewhat well characterized with RAL, when used in combination with TDF/FTC, 83 
8,9 there is little information when RAL is combined with DRV/r in a randomised study. 84 
Therefore, the objective of the present study, was to describe the full resistance profile at 85 
virological failure and to determine factors associated with the development of IN-resistance 86 
mutations. 87 
 METHODS 88 
Study design  89 
NEAT 001/ANRS 143 was an European open-label, non-inferiority, phase III randomised trial 90 
conducted in 15 European countries. Eight hundred five participants were randomised in a 91 
1/1 ratio to receive 400 mg twice daily raltegravir plus 800 mg darunavir and 100 mg 92 
ritonavir once daily  (n=401) or tenofovir/emtricitabine in a 245 and 200 mg fixed dose 93 
combination once daily plus 800 mg of darunavir and 100 mg of ritonavir once daily (n= 404). 94 
Eligible individuals had baseline plasma VL > 1000 copies/mL and no evidence of major IAS-95 
USA resistance mutations 10 on genotype testing, historically or at screening. The primary 96 
endpoint was the time to virological or clinical failure, with preplanned subgroup analyses of 97 
the primary endpoint by baseline CD4 cell count and HIV-1 RNA concentration. Ethics 98 
committee approval was obtained from all participating centres, in accordance with the 99 
principles of the Declaration of Helsinki. All trial participants gave written informed consent. 100 
 101 
Genotypic resistance analyses and interpretation 102 
The criteria for genotypic testing was a confirmed viral load (VL) > 50 copies/mL or any single 103 
VL > 500 copies/mL at or after W32. In addition, insufficient virological response was defined 104 
as decrease <1 log10 copies per mL in HIV-1 RNA concentration at week 18, or an HIV-1 RNA 105 
concentration ≥ 400 copies/per mL at week 24. In this situation of insufficient virological 106 
response before week 32, decision to perform genotypic testing and/or change in treatment 107 
was optional and left to the clinician.7 Although protocol-defined virological failure was 108 
considered at or after W32, genotypes done before because of insufficient virological 109 
response were included in the resistance analysis. In patients with multiple virological 110 
 failures, we analysed all available resistance tests available, resistance developed on second-111 
line therapy was not considered in the analysis. Bulk sequences of the reverse transcriptase 112 
(RT), protease and integrase (IN) genes on RNA were determined using the ANRS consensus 113 
technique primer sequences described at http://www.hivfrenchresistance.org . In the main 114 
results paper,7 resistance mutations were interpreted according to the 2009 IAS-USA list of 115 
mutations (reference list used at time of inclusion) and in the present study with the 2014 116 
IAS-USA version 11.  A genotypic testing at baseline was performed for RT and protease 117 
genes, at each site local laboratory and for RT, protease and IN genes at virological failure, 118 
mainly in the Pitié-Salpêtrière Virology Laboratory. Only data from participants with a 119 
successful genotypic test were available for the analyses. To assess potential factors 120 
associated with resistance development in participants treated with DRV/r + RAL, the 121 
baseline characteristics of viral load and CD4+ T-cell count were evaluated. 122 
 123 
Statistical analyses 124 
The Kaplan Meier method was used to estimate cumulative proportion of patients with IN 125 
resistance in the NtRTI-sparing strategy, assuming that patients who did not virologically fail 126 
did not develop resistance. Chi squared tests, rank sum tests and tests for trend were used 127 
to compare characteristics at baseline and failure between participants who developed at 128 
least one IN resistance mutation and those who did not. 129 
 130 
 131 
 132 
 RESULTS 133 
Overall , 127 participants  (69/401 in the RAL+DRV/r arm and 58/404 in the TDF/FTC+DRV/r 134 
arm) met the criteria for genotypic testing with, at or after W32, either a confirmed viral 135 
load (VL) > 50 copies/mL or at least one VL > 500 copies/mL. Baseline characteristics of 136 
participants are reported in table 1. At least one resistance test was obtained for 110 137 
participants (61 in the RAL+DRV/r arm and 49 in the TDF/FTC+DRV/r arm), although not all 138 
tests were successful in all genes. Median (IQR) HIV RNA at time of genotype testing was 139 
significantly different in participants who failed between the 2 arms: 373 copies/mL (IQR: 140 
110-1064) in the RAL+DRV/r arm vs 133 copies/ml (IQR: 67-568) in the TDF/FTC+DRV/r arm; 141 
p-value=0.02). In the TDF/FTC+DRV/r arm, among the 49 participants who met criteria for 142 
genotypic testing and successfully had genotypic resistance test, no major IAS-USA 143 
resistance mutations were observed; thus all further analyses are limited to the RAL+DRV/r 144 
arm. Of the 61 genotypes tested in the RAL+DRV/r arm, we obtained 55, 53 and 57 145 
sequences for IN, RT and protease gene, respectively. At baseline none had major IAS RT and 146 
protease resistance mutations detected by Sanger sequencing.  In those with at least one 147 
successful genotypic test, 15/55 (27.3%) in the RAL DRV/R arm had viruses with IN resistance 148 
mutations (12 N155H alone, 1 N155H + Q148R, 1 F121Y and 1 Y143C), 2/53 (3.8%) with 149 
NtRTI resistance mutations (K65R, M41L), and 1/57 (1.8%) with a primary protease mutation 150 
(L76V) (Table 2). Three patients presented minor IN resistance mutations (L74M or T97A) 151 
that could be interpreted as polymorphisms. The cumulative risk in patients in the DRV/r 152 
+RAL to experience virological failure and emergent IN resistance associated mutations was 153 
2.1% (95% CI 1.0-4.1) at week 48 and 3.9% (95% CI 2.4-6.4) at week 96. HIV-1 RNA values at 154 
failure were not significantly different in those who failed with or without an IN mutation 155 
(median 731 copies/mL (IQR: 192, 14864) vs. 351 copies/mL (IQR: 134-904); p=0.17. The 156 
 proportion of patients in the RAL arm who achieved full virological success when switched to 157 
a different regimen (mostly RAL changed to TDF/FTC) was similar in those who switched 158 
after failure with resistance (13/15 = 86.7 %) and in those those who switched after failure 159 
without resistance (27/34 = 79.4 %). The frequency of IN mutations at failure was 160 
significantly associated with baseline VL: 7.1% (1/14) for participants harbouring a baseline 161 
VL < 100,000 copies/mL, 25.0% (7/28) for a baseline VL ≥ 100-500,000 copies/mL, and 53.8% 162 
(7/13) for a baseline VL ≥ 500,000 copies/mL (PTREND=0.007). Although prespecified subgroup 163 
analysis showed that the NtRTI-sparing regimen was inferior to the standard regimen group 164 
in patients with baseline CD4 count of <200 cells/ μL there was no statistically significant 165 
difference in the proportion of IN resistance between patients with a baseline CD4 count 166 
<200 cells/μL compared to those above (36.8 % vs. 22.2%, p-value=0.25). 7 Of note, 4/15 167 
participants with IN resistance mutations had a VL < 200 copies/mL at the time of testing. 168 
Figure 1 shows the time to detection of IN resistance mutations on RAL+DRV/r (based on all 169 
participants in this arm), that tended to emerge early (between 19 and 96 weeks).  170 
 171 
DISCUSSION 172 
 NEAT 001/ANRS 143 was a phase 3 trial of NtRTI sparing regimen which compared an 173 
integrase strand transfer inhibitor (raltegravir) to a NtRTI standard backbone 174 
(tenofovir/emtricitabine) in first line therapy with a boosted protease inhibitor (darunavir/r). 175 
This trial showed that RAL+DRV/r regimen was overall non inferior to standard treatment for 176 
antiretroviral-naïve participants, but inferior for those with a CD4 count < 200 cells/μL.  177 
Through week 96, a high proportion of participants treated with either regimen had viral 178 
load suppression (HIV-1 RNA < 50 copies/mL in 78.6% and 82.2% for NtRTI-sparing group and 179 
 standard group)7. However the NtRTI-sparing regimen RAL+DRV/r was associated with 180 
higher rates of virological failure in those with baseline CD4 counts < 200 cells/μL 7 and was 181 
associated with selection of resistance mutations at virological failure, especially to IN. 182 
Whereas no resistance mutations were found in genotype of participants with virological 183 
failure from the standard arm, IN mutation resistance was observed in more than one-184 
quarter of samples at failure in the RAL+DRV/r arm. Our results confirm very well established 185 
data on the almost absence of development of protease resistance-associated mutations at 186 
virological failure in patients on a first-line ritonavir boosted protease inhibitor combined 187 
with 2 NtRTI, 12,13 while such resistance mutations is more likely when a ritonavir-boosted 188 
protease inhibitor is combined with NNRTI, 14 or, to a lesser extent, with integrase strand 189 
transfer inhibitor. 15 These data suggest a mutual bidirectional protection of NtRTI and PI/r 190 
when combined with regards to resistance selection, 16 as illustrated by the total absence of 191 
selection of reverse transcriptase or protease resistance-associated mutations in the 49 192 
virological failures on ritonavir-boosted darunavir + tenofovir/emtricitabine.  193 
However we cannot exclude that resistance mutations are selected outside the protease 194 
gene such as gag-pol cleavage sites and gp4116–18 and this question should be examined in 195 
future studies. In NEAT 001, the cumulative risk of integrase resistance at virological failure 196 
in patients treated with DRV/r + RAL at W48 was 2.1%, which is higher than the cumulative 197 
risk of resistance development reported in other studies with raltegravir + 198 
tenofovir/emtricitabine given as first-line therapy, ranging from 0.2% 19 to 1.4% 20 at W48. 199 
Such higher rate of integrase resistance has been reported in previous studies of raltegravir 200 
+ ritonavir-boosted protease inhibitor. In the Spartan study, a randomised controlled 201 
multicentre pilot study in 94 naïve HIV infected participants received atazanavir plus RAL or 202 
ritonavir-boosted atazanavir plus TDF/FTC. After 24 weeks of follow-up, 4 (6.3%) participants 203 
 in the NRTI-sparing arm failed with development of IN resistance mutations, while no 204 
resistance mutations were observed in the control arm. Three of the 4 participants with 205 
resistance at failure had baseline HIV-1 RNA > 500,000 copies/mL.21  206 
In the PROGRESS pilot study, comparing the NtRTI sparing regimen of lopinavir/r plus RAL 207 
with the standard of care regimen of lopinavir/r plus TDF/FTC in naïve HIV infected patients, 208 
8 subjects in the LPV/r+RAL failed, 3 of them with IN resistance mutations (3.7%). One   of 209 
them had also an emergent major protease mutation; conversely, in the TDF/FTC arm only 210 
1/5 patients who failed   had a M184V mutation. 15  Whether these differences are related to 211 
the different backbones, 2 NtRTI or ritonavir-boosted protease, in combination with 212 
raltegravir, or to differences in resistance testing and analysis is unknown. One could 213 
hypothesize that, similarly to what is observed with PI/r therapy, TDF/FTC confers some 214 
protection to the risk of resistance emergence at virological failure with raltegravir therapy. 215 
The mechanism of this NtRTI protection could be an undiscovered molecular interaction 216 
within the HIV replication cycle or more probably a consequence of the very long half-life of 217 
intracellular tenofovir and emtricitabine, providing forgiveness to the great variability of 218 
raltegravir exposure. On the contrary, despite its high genetic barrier to resistance, 219 
darunavir/ritonavir, with relative short half-life, might confer less forgiveness to raltegravir, 220 
especially in situations of partial or intermittent non-adherence. Further analyses will assess 221 
adherence and raltegravir plasma concentrations in NEAT 001 to elucidate reasons for the 222 
high rate of resistance emergence, especially in patients with high baseline viral load. On the 223 
other hand, differences in assays used for resistance testing in the various studies should be 224 
considered, and more importantly, different timepoints of analysis (first of confirmed 225 
virological failure sample) and level of viral load at the time of genotyping, which might 226 
greatly influence genotype results. 22 This renders cross study comparisons hazardous with 227 
 regards to the prevalence of resistance at virological failure. Indeed, in NEAT 001, resistance 228 
analysis population differed from those of previous studies of raltegravir + 229 
tenofovir/emtricitabine,19,20 or of a pilot uncontrolled study of raltegravir + 230 
darunavir/ritonavir. 23  In the latter study, ACTG 5262, rate of integrase resistance at virologic 231 
failure was 4.5%; 5 out of 25 patients with virological failure and genotype testing had 232 
integrase resistance mutations at virological failure and a baseline viral load > 100,000 233 
copies/ml. In NEAT 001, the proportion of participants in the DRV/r + RAL group with 234 
baseline viral load > 100,000 copies/ml who experienced virological failure and emergent 235 
integrase resistance-associated mutations was 9.6% versus 10.4% in ACTG 5262.23 Initiating 236 
antiretroviral therapy with the combination of ritonavir-boosted darunavir + raltegravir in 237 
patients with high baseline viral load is associated with an unacceptable high risk of 238 
raltegravir resistance on treatment, particularly in those with HIV-1 RNA > 500,000 239 
copies/ml; 27.3% developed resistance on treatment in our study. The main selected IN 240 
mutation in our study was the N155H raltegravir signature mutation alone, so most viruses 241 
at virological failure remained, in theory, susceptible to dolutegravir, except for the one 242 
harbouring the F121Y mutation which confers phenotypic resistance to dolutegravir as 243 
well.24The uncontrolled pilot VIKING 3 study have shown the efficacy of dolutegravir twice a 244 
day on raltegravir failure with the mutation N155H alone. 25 However, great caution and 245 
more clinical studies are needed, as recent data suggest that dolutegravir might also select 246 
for N155H and that viruses harbouring such mutation might have diminished susceptibility 247 
to dolutegravir when used once daily. 26 One limitation of our study is the absence of 248 
genotypic information, due to either absence of available sample or failure to obtain 249 
sequence in 12% of participants qualifying for resistance testing in the RAL + DRV/r arm. This 250 
proportion was 16% in the TDF/FTC + DRV/r arm.  Another limitation of our study is that the 251 
 protocol did not ask for IN gene sequence at baseline, as at the time of recruitment there 252 
was little clinical use of integrase inhibitors and a risk of transmitted drug resistance was 253 
very low for the integrase class (1.7% for IN resistance mutation in the PRIMO cohort of 254 
recently infected patients).27 Although we cannot formally exclude that some participants 255 
might have had IN resistance pre-existing to initiation of therapy, this is highly unlikely, as 256 
N155H mutation confers high level phenotypic resistance to raltegravir and in such 257 
circumstance, virological failure would have occurred much more rapidly, without the early 258 
virological suppression seen in 9/13 patients with N155H mutation.  Although none of the RT 259 
(n = 2) and protease (n = 1) resistance mutations evidenced at failure were detected at 260 
baseline using Sanger sequencing, ultradeep sequencing on those baseline samples could 261 
help to determine if these emergent RT (M41L, K65R) and protease (L76V) mutations are 262 
due to selection or re-emergence of transmitted minority resistant variants. Of clinical 263 
relevance, IN resistance was seen in patients (4/15) with very low-level viremia (HIV RNA 264 
between 50 and 200 copies/mL), a phenomenon already described in the ACTG 5262 study. 265 
23 In another study on risk factors for raltegravir resistance development in clinical practice, 266 
we showed that 7.7 % (6/78) of patients with HIV RNA between 50 and 200 copies/mL had 267 
IN resistance mutations. 28 Thus, viral rebound with 2 consecutive HIV RNA values > 50 268 
copies should be considered as definite virological failure in patients receiving DRV/r + RAL, 269 
and genotypic resistance testing should be performed without delay in these patients  270 
 In summary, during 96-weeks of follow up, resistance to IN was detected in 15/401 271 
participants randomised to DRV/r+RAL (3.7%). One quarter (27%) of samples at failure had 272 
IN resistance mutations, with risk of resistance related to baseline HIV RNA. Most patients 273 
with resistance mutations achieved complete suppression when switched to other regimens, 274 
most often TDF/FTC instead of RAL, with continuation of ritonavir-boosted darunavir.  275 
 It would be interesting to investigate other NtRTI sparing strategies combining an ISTI with a 276 
higher genetic barrier to resistance and a longer half-life such as dolutegravir , in 277 
combination with a boosted-protease inhibitor. Based on these results on resistance, 278 
initiation of antiretroviral therapy with the alternative regimen of ritonavir-boosted 279 
darunavir and raltegravir in patients with CD4 > 200/μL should be limited to patients with 280 
HIV RNA < 500,000 copies/ml, and discussed  in patients with HIV RNA between 100,000 and 281 
500,000 copies/ml. 282 
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 600 
Table 1 : Baseline characteristics of patients meeting criteria for genotypic testing 601 
  RAL+DRV/r (n=69) TDF+FTC+DRV/r (n=58) 
Sex   
Male 65 (94%) 50 (86%) 
Median (IQR) age (years) 37 (32-44) 39 (31-52) 
Ethnic origin   
White 53 (77%) 45 (78%) 
Black 12 (17%) 10 (17%) 
Asian 1 (1%) 2 (3%) 
Other 3 (4%) 1 (2%) 
Mode of HIV infection    
Homosexual/bisexual sex 40 (63%) 32 (58%) 
Heterosexual 23 (37%) 20 (36%) 
IVDU 0 2 (4%) 
Other 0 1 (2%) 
HIV CDC clinical stage   
A 54 (78%) 47 (81%) 
B 10 (15%) 7 (12%) 
C 5 (7%)  4 (7%) 
Median (IQR) CD4 cell count (cells per μL) 295 (150-378) 316 (205-379) 
CD4 cell count category (cells per μL)   
<50 3 (4%) 3 (5%) 
50-199 19 (28%) 11 (19%) 
200-349 24 (35%) 21 (36%) 
350-499 20 (29%) 22 (38%) 
 ≥500 3 (4%) 1 (2%) 
Median (IQR) HIV-1 RNA concentration at 
baseline (log10 copies per mL) 5.25 (4.85-5.58) 5.19 (4.80-5.54) 
Baseline HIV-1 RNA category   
≥100 000 copies per mL 49 (71%) 36 (62%) 
≥500 000 copies per mL 14 (20%) 9 (16%) 
HCV co-infection 3 (4%) 4 (7%) 
 602 
 603 
 604 
 605 
 606 
Figure 1: time to detection of IN resistance mutations, RAL + DRV/r arm, NEAT 001/ANRS 143  607 
trial 608 
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 618 
Table 2 : Resistance mutations in the RAL+DRV/r arm 619 
Patients Genotypic testing RT PROT IN Subsequent regimen VL at W96 
(copies/mL) 
Suppressed 
before 
resistance test 
 
Time VL 
(copies/mL) 
  
1 W47 247  L76V  RAL+DRV/r <50 Y 
2 W38 340 M41L   TDF/FTC+EFV then 
TDF/FTC+DRV/r 
<50 N 
3 W65 3800 K65R   TDF/FTC+DRV/r <50 Y 
4 W24 64041   N155H TDF/FTC+DRV/r 107 N 
5 W58 60   Y143C TDF/FTC+DRV/r 90 Y 
6 W32 85   N155H TDF/FTC+DRV/r <50 N 
7 W34 148   N155H No treatment after W67 227185 Y 
8 W64 192   N155H TDF/FTC+DRV/r 68 Y 
 9 W62 406   N155H TDF/FTC+DRV/r <50 Y 
10 W29 442   N155H 
+Q148R 
Missing data Missing data Y 
11 W49 498   N155H RAL+DRV/r <50 Y 
12 W79 731   N155H ABC/3TC+DRV/r <50 Y 
13 W32 1311   N155H TDF/FTC+DRV/r <50 Y 
14 W34 1900   N155H TDF/FTC+ETR <50 Y 
15 W21 14864   N155H TDF/FTC+EFV <50 N 
16 W19 52857   N155H AZT/3TC+DRV/r+NVP <50 N 
17 W74 129000   N155H RAL+DRV/r 50 Y 
18 W96 1470   F121Y RAL+DRV/r 1470 Y 
 620 
RT : reverse transcriptase ; PROT : protease ; IN ; integrase ; VL : viral load ; W96 : 96 week ; 621 
copies/mL : copies/mililiter ; Y : yes ; N : No ; RAl : raltegravir ; DRV/r : darunavir/ritonavir ; 622 
TDF : tenofovir ; EFV : efavirenz ; FTC : emtricitabine ; ABC/3TC : abacavir/lamivudine ; ETR : 623 
etravirine ; NVP : nevirapine ; RPV : rilpivirine 624 
